Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK
Open Access
- 5 December 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 96 (1) , 143-150
- https://doi.org/10.1038/sj.bjc.6603501
Abstract
To predict the public health impact on cervical disease by introducing human papillomavirus (HPV) vaccination in the United Kingdom, we developed a mathematical model that can be used to reflect the impact of vaccination in different countries with existing screening programmes. Its use is discussed in the context of the United Kingdom. The model was calibrated with published data. The impact of vaccination on cervical cancer and deaths, precancerous lesions and screening outcomes were estimated for a vaccinated cohort of 12-year-old girls, among which it is estimated that there would be a reduction of 66% in the prevalence of high-grade precancerous lesions and a 76% reduction in cervical cancer deaths. Estimates for various other measures of the population effects of vaccination are also presented. We concluded that it is feasible to forecast the potential effects of HPV vaccination in the context of an existing national screening programme. Results suggest a sizable reduction in the incidence of cervical cancer and related deaths. Areas for future research include investigation of the beneficial effects of HPV vaccination on infection transmission and epidemic dynamics, as well as HPV-related neoplasms in other sites.Keywords
This publication has 36 references indexed in Scilit:
- Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccinationVaccine, 2006
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysisThe Lancet, 2005
- Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical CancerCancer Epidemiology, Biomarkers & Prevention, 2005
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Carcinogenicity of human papillomavirusesThe Lancet Oncology, 2005
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialThe Lancet, 2004
- Evaluating Human Papillomavirus Vaccination ProgramsEmerging Infectious Diseases, 2004
- Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical CancerJNCI Journal of the National Cancer Institute, 1999
- Natural History of Dysplasia of the Uterine CervixJNCI Journal of the National Cancer Institute, 1999